Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Series B Financing
NeoPhore Closes Oversubscribed Series B Round with Funding from Bristol Myers Squibb
Details : NeoPhore will explore novel biology associated with the DNA MMR pathway in cancer and progress its pre-clinical studies of small molecule drugs targeting novel proteins across the MMR pathway.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 22, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Series B Financing
Lead Product(s) : NP1867
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Sixth element capital
Deal Size : $39.5 million
Deal Type : Series B Financing
NeoPhore Raises £9.6M in Series B Extension to Advance Drug Discovery Pipeline
Details : The net proceeds will be used to progress NeoPhore's lead canditate, NP1867, an oral, small molecule, first-in-class MMR inhibitor, through early pre-clinical development in solid tumours.
Brand Name : NP1867
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 01, 2024
Lead Product(s) : NP1867
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Sixth element capital
Deal Size : $39.5 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : The Institute of Cancer Research
Deal Size : Undisclosed
Deal Type : Collaboration
NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London
Details : The collaboration will use NeoPhore's proprietary small molecule inhibitors of DNA mismatch repair to investigate single agent activity against tumours with defined genetic backgrounds.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : The Institute of Cancer Research
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : CRT Pioneer Fund
Deal Size : $28.5 million
Deal Type : Series B Financing
NeoPhore Completes Extension To Series B Financing To Further Advance Discovery Pipeline
Details : The additional funding will be used to progress NeoPhore's expanding pipeline of drugs, encompassing multiple biological targets and modalities of treatment, to the start of IND-enabling studies in 2024.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 19, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : CRT Pioneer Fund
Deal Size : $28.5 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?